Monday, February 25, 2008

Amgen Foundation Expands Giving to Europe

The Amgen Foundation is proud to expand its philanthropic giving to organizations chartered in Europe through a partnership with United Way International (UWI). Charitable giving is a tangible demonstration of Amgen’s core values and reflects responsible use of limited funds which create value through programs that have a real impact.

Read the rest of this entry

Posted in Philanthropy

Thursday, February 07, 2008

Amgen Award for Science Teaching Excellence (AASTE) Program Overview

Amgen, a biotechnology pioneer, discovers, develops, manufactures and markets important human therapeutics for serious illnesses. Amgen is committed to dramatically improving people’s lives – not only through the therapeutics we deliver to patients but also through supporting programs that advance science literacy throughout North America.

Read the rest of this entry

Posted in Philanthropy

Monday, February 04, 2008

Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates

THOUSAND OAKS, Calif. & OSAKA, Japan, Feb 04, 2008 – Amgen (NASDAQ:AMGN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced an agreement under which Takeda will develop and commercialize for the Japanese market up to 13 molecules from Amgen’s pipeline, one of which is included as an option. This collaboration validates the significant value of Amgen’s clinical stage pipeline and further ensures Japanese patients will have access to Amgen’s innovative potential medicines for serious illnesses. The collaboration includes early to mid-stage clinical-stage candidates across a range of therapeutic areas, including oncology, inflammation, and pain.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Friday, February 01, 2008

New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque Psoriasis

SAN ANTONIO, Texas – Feb. 1, 2008 – Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group. These results will be presented today at the American Academy of Dermatology Scientific Meeting in San Antonio, Texas.

Read the rest of this entry

Posted in Press Releases, Product News